Immunotherapy requires purified cells for a variety of experimental needs. For patients with protein deficiencies for whom gene therapy is not an option, B cells provide an excellent factory for producing immunoglobulin in lymphocytes or plasma cells.
Obtaining a large number of B cells requires a cell isolation solution for both pre-clinical testing on a small or large scale and clinical applications. The new MARS Bar system enables positive or negative immuno-magnetic CD19+ cell isolation for separation from a variety of cell products.
